JERUSALEM--(BUSINESS WIRE)--Jan. 29, 2006--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company’s ANDA for Desmopressin Acetate Tablets, 0.1 mg and 0.2 mg. Teva’s Desmopressin Acetate Tablets are the AB-rated generic equivalent of Aventis’ DDAVP(R) Tablets, a product indicated for management of central diabetes insipidus, temporary polyuria and polydipsia following head trauma or surgery in the pituitary region, and primary nocturnal enuresis.
